AIM ImmunoTech Inc. (NYSE American: AIM) began a rights offering on February 11, 2026 that will raise $12 million in gross proceeds. The offering allows all holders of record of the company’s common stock, as well as holders of certain options and warrants, to purchase up to 12,000 units at $1,000 per unit. Each unit consists of one share of Series G Convertible Preferred Stock and 1,666 warrants to buy common stock at $1.20 per share. The rights are non‑transferable and must be exercised by 5:00 p.m. Eastern Time on February 27, 2026, unless the company extends the period.
The primary purpose of the offering is to provide additional working capital to support ongoing clinical programs and to strengthen the balance sheet amid liquidity challenges. AIM’s cash position was $835,000 as of June 30, 2025, and the company has reported net losses of $2.8 million in Q2 2025 and $1.8 million in Q2 2024. Negative operating and net margins of –13,006.25 % and –14,062.5 % respectively, combined with a distressed Altman Z‑Score of –120.52, underscore the urgency of raising capital. The company also received a warning from NYSE American for non‑compliance with minimum stockholders’ equity requirements, with a deadline to regain compliance by June 11, 2026.
Investors reacted negatively to the announcement, citing the dilutive nature of the rights offering and the company’s precarious financial position. The offering’s dilution potential, coupled with the company’s ongoing losses and regulatory compliance concerns, contributed to a cautious market response.
AIM’s clinical focus remains on Ampligen®, a rintatolimod candidate for late‑stage pancreatic cancer, in collaboration with AstraZeneca’s Imfinzi® (durvalumab) in the DURIPANC study. Positive interim results from the DURIPANC trial have shown potential survival benefits, providing a key clinical milestone that the company hopes to build on with the additional capital raised. The rights offering is therefore a critical step to secure funding for these programs while addressing immediate liquidity needs.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.